1 Min Read
April 6 (Reuters) - Newlink Genetics:
* IN LIGHT OF INCYTE’S ANNOUNCEMENT REGARDING ECHO-301 TRIAL, CO UNDERTAKING REVIEW OF CLINICAL PROGRAMS Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.